Bartosz Chmielowski
Experienced in Dendritic Cell Tumor

Dr. Bartosz Chmielowski

Hematology | Oncology
The Regents Of The University Of California
900 Weyburn Place, Suite 14 171, 
Los Angeles, CA 
Offers Telehealth
Experienced in Dendritic Cell Tumor
The Regents Of The University Of California
900 Weyburn Place, Suite 14 171, 
Los Angeles, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Bartosz Chmielowski is a Hematologist and an Oncologist in Los Angeles, California. Dr. Chmielowski is rated as an Experienced provider by MediFind in the treatment of Dendritic Cell Tumor. His top areas of expertise are Melanoma, Adult Soft Tissue Sarcoma, Metastatic Uveal Melanoma, Vulvectomy, and Tissue Biopsy.

His clinical research consists of co-authoring 125 peer reviewed articles and participating in 19 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Oncology
Licenses
Internal Medicine in CA
Hospital Affiliations
Ronald Reagan UCLA Medical Center
Santa Monica - UCLA Med Ctr & Orthopaedic Hospital
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Chinese Community Health
  • HMO
  • MEDICARE SNP
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Kaiser Permanente
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER MEDICARE
  • POS
  • PPO
LA Care
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Nippon Life
  • INSURANCE PLAN
Oscar
  • EPO
  • HMO
  • PPO
SCAN Health Plan
  • INSURANCE PLAN
  • MEDICARE MAPD
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 13 Less Insurance Carriers -

Locations

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
900 Weyburn Place, Suite 14 171, Los Angeles, CA 90095
Other Locations
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
757 Westwood Plz, Suite 7501, Los Angeles, CA 90095
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
2020 Santa Monica Blvd, Suite 210, Santa Monica, CA 90404

Additional Areas of Focus

Dr. Chmielowski has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma
Neurofibromatosis Type 1 (NF1)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

18 Clinical Trials

A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
A Phase II Randomized Study of Adjuvant Versus NeoAdjuvant Pembrolizumab (MK-3475) for Clinically Detectable Stage III-IV High-Risk Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
A Randomized Phase II Trial of Intermittent Versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Procedure, Drug
Study Drugs: Dabrafenib Mesylate, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 2
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients With High Risk Resected Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: September 22, 2025
Intervention Type: Other, Procedure, Biological
Study Drugs: Ipilimumab, Pembrolizumab, Recombinant Interferon Alfa-2b
Study Phase: Phase 3
A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
A Phase II and Pilot Trial of PD-1 Blockade With Pembrolizumab (MK-3475) in Patients With Resectable or Unresectable Desmoplastic Melanoma (DM)
Enrollment Status: Active_not_recruiting
Publish Date: September 17, 2025
Intervention Type: Procedure, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 2
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
DREAMseq (Doublet, Randomized Evaluation in Advanced Melanoma Sequencing) a Phase III Trial
Enrollment Status: Active_not_recruiting
Publish Date: September 16, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Dabrafenib Mesylate, Ipilimumab, Nivolumab, Trametinib Dimethyl Sulfoxide
Study Phase: Phase 3
A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
A Phase Ib/II Study of APG-115 as a Monotherapy or in Combination With Pembrolizumab in Patients With Unresectable or Metastatic Melanomas or Advanced Solid Tumors
Enrollment Status: Active_not_recruiting
Publish Date: August 07, 2025
Intervention Type: Drug
Study Drug: APG-115+Pembrolizumab
Study Phase: Phase 1/Phase 2
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
A Phase II Randomized, Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 Compared With Investigator Choice in HLA-A*0201 Positive Patients With Previously Untreated Advanced Uveal Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: August 01, 2025
Intervention Type: Biological, Drug
Study Drugs: IMCgp100, Dacarbazine, Ipilimumab, Pembrolizumab
Study Phase: Phase 2
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2025
Intervention Type: Drug
Study Drugs: LXH254, LTT462, Trametinib, Ribociclib
Study Phase: Phase 2
A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
A Phase 2 Open-Label Multicenter Study to Evaluate the Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma
Enrollment Status: Terminated
Publish Date: August 23, 2024
Intervention Type: Drug
Study Drugs: Selinexor, Pembrolizumab
Study Phase: Phase 2
A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)
A Phase 2, Open-label, Multicenter Study Evaluating the Safety and Efficacy of Autologous Tumor-infiltrating Lymphocytes (TILs) in Subjects With Advanced Melanoma (DELTA-1)
Enrollment Status: Terminated
Publish Date: April 16, 2024
Intervention Type: Biological
Study Drug: ITIL-168
Study Phase: Phase 2
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
A Phase III Study of AL3818 (Anlotinib, Catequentinib) Hydrochloride Monotherapy in Subjects With Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma
Enrollment Status: Active_not_recruiting
Publish Date: January 31, 2024
Intervention Type: Drug
Study Drugs: Anlotinib, Decarbazine
Study Phase: Phase 3
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms
A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms
Enrollment Status: Completed
Publish Date: December 21, 2023
Intervention Type: Biological
Study Drugs: MGD013, MGD013+Margetuximab
Study Phase: Phase 1
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)
Enrollment Status: Completed
Publish Date: January 23, 2023
Intervention Type: Drug
Study Drug: Selinexor
Study Phase: Phase 2/Phase 3
A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1a/1b, Open-label First-in-human Study of the Safety, Tolerability and Feasibility of Gene-edited Autologous NeoTCR-T Cells (NeoTCR-P1) Administered as a Single Agent or in Combination With Anti-PD-1 to Patients With Locally Advanced or Metastatic Solid Tumors
Enrollment Status: Suspended
Publish Date: August 18, 2022
Intervention Type: Biological
Study Drugs: NeoTCR-P1 Adoptive Cell Therapy, Nivolumab, IL-2
Study Phase: Phase 1
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
A Phase 1b (Open-Label)/Phase 2 (Randomized, Double-Blinded) Study Evaluating Gemcitabine and Docetaxel With or Without Olaratumab in the Treatment of Advanced Soft Tissue Sarcoma
Enrollment Status: Completed
Publish Date: May 09, 2022
Intervention Type: Drug
Study Drugs: Olaratumab, Gemcitabine, Docetaxel
Study Phase: Phase 1/Phase 2
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
A Phase 1, Open-Label, Dose Escalation Study of MGA271 in Combination With Ipilimumab in Patients With Melanoma, Non-Small Cell Lung Cancer, and Other Cancers
Enrollment Status: Completed
Publish Date: February 08, 2022
Intervention Type: Biological
Study Phase: Phase 1
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Enrollment Status: Completed
Publish Date: February 08, 2022
Intervention Type: Biological
Study Phase: Phase 1
An Open-label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX005M) or Ipilimumab With Nivolumab in Patients With Advanced or Metastatic Melanoma
An Open-label, Phase 1B Study of NEO-PV-01 + CD40 Agonist Antibody (APX005M) or Ipilimumab With Nivolumab in Patients With Advanced or Metastatic Melanoma
Enrollment Status: Terminated
Publish Date: September 03, 2020
Intervention Type: Biological, Other
Study Phase: Phase 1
View 17 Less Clinical Trials

125 Total Publications

RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).
RP1 Combined With Nivolumab in Advanced Anti-PD-1-Failed Melanoma (IGNYTE).
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: July 08, 2025
Similar Doctors
Advanced in Dendritic Cell Tumor
Dr. Eric M. Cheung
Oncology | Hematology
Advanced in Dendritic Cell Tumor
Dr. Eric M. Cheung
Oncology | Hematology
3300 East South Street, Suite 304, 
Lakewood, CA 
 (20.6 miles away)
562-232-0550
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Eric Cheung is a Hematologist and an Oncologist in Lakewood, California. Dr. Cheung is rated as an Advanced provider by MediFind in the treatment of Dendritic Cell Tumor. His top areas of expertise are Thrombocytopenia, Febrile Neutropenia, Agranulocytosis, and Chronic Familial Neutropenia. Dr. Cheung is currently accepting new patients.

Advanced in Dendritic Cell Tumor
Dr. Chatchada Karanes
Hematology | Oncology
Advanced in Dendritic Cell Tumor
Dr. Chatchada Karanes
Hematology | Oncology
1500 E Duarte Rd, 
Duarte, CA 
 (27.6 miles away)
626-359-8111
Languages Spoken:
English
See accepted insurances

Chatchada Karanes is a Hematologist and an Oncologist in Duarte, California. Dr. Karanes is rated as a Distinguished provider by MediFind in the treatment of Dendritic Cell Tumor. Her top areas of expertise are Multiple Myeloma, Acute Myeloid Leukemia (AML), Relapsed Refractory Multiple Myeloma (RRMM), Bone Marrow Transplant, and Bone Marrow Aspiration.

Advanced in Dendritic Cell Tumor
Dr. Hao W. Zhang
Hematology Oncology | Hematology | Oncology
Advanced in Dendritic Cell Tumor
Dr. Hao W. Zhang
Hematology Oncology | Hematology | Oncology

Hao Wei Zhang MD Inc

1700 E Cesar E Chavez Ave, Suite 2600, 
Los Angeles, CA 
 (13.3 miles away)
323-264-7238
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hao Zhang is a Hematologist Oncology specialist and a Hematologist in Los Angeles, California. Dr. Zhang is rated as a Distinguished provider by MediFind in the treatment of Dendritic Cell Tumor. His top areas of expertise are Anemia, Plasmacytoma, Choriocarcinoma, and Inflammatory Breast Cancer.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Chmielowski's expertise for a condition
ConditionClose
View All 18 Distinguished Conditions
View All 9 Advanced Conditions
View All 75 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile